KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia

Abstract Blast phase chronic myeloid leukemia (BP-CML) poses significant clinical challenges due to its drug resistance, resulting from BCR::ABL1-dependent mutations and BCR::ABL1-independent pathways. Previously, we reported that FLT3 pathway is activated in ~ 50% of BP-CML cases, indicating a pote...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Hyun-Jin Kwon, Ji Eun Shin, Amir Khan, So Yeon Park, Jiyoung Kim, Jee-Young Lee, Doohyun Lee, Seungyeon Lee, Chun Young Im, Heegyum Moon, Ye Ri Han, Minori Tamai, Koshi Akahane, Takeshi Inukai, Wonhwa Lee, Hyelim Kim, Hong Nam Kim, Sung-Min Ahn, Hyun Woo Park, Dong-Wook Kim
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2025-04-01
سلاسل:	Molecular Cancer
الموضوعات:	KF1601 Chronic myeloid leukemia (CML) Chronic phase CML (CP-CML) Blast phase CML (BP-CML) Tyrosine kinase inhibitor (TKI) TKI resistance
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12943-025-02292-z
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!